Large trade alert! Gland Pharma shares fall 3% after 1.2 crore shares change hands in 2 block deals; promoter Fosun likely seller

Shares of Gland Pharma declined 3% to the day’s low of Rs 2,827 on the BSE on Friday after 1.22 crore shares changed hands in two separate block deals worth Rs 2,941 crore and Rs 2,877 crore, respectively.

According to various reports, Fosun Pharma Industrial was looking to divest a 5% stake in the company through a block deal. As of June 30, 2026, Fosun Pharma Industrial held 8,53,93,894 shares, representing a 51.77% stake in Gland Pharma, according to BSE data.

The reported stake sale was priced at a floor price of Rs 2,763 per share, representing a discount of around 5% to Gland Pharma’s previous closing price. The offer size was pegged at Rs 2,279.5 crore, with a lock-up of up to 12 months on any further sale of shares, according to multiple media reports.


Separately, Gland Pharma informed the exchanges on September 1 that the United States Food and Drug Administration (USFDA) had conducted a routine Good Manufacturing Practice (GMP) inspection at its VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam between August 24 and September 1, 2026. The inspection concluded with zero Form 483 observations.

Gland Pharma Q1 results

Gland Pharma reported a consolidated net profit of Rs 317 crore for Q1FY27 on August 10, up 47% year-on-year from Rs 216 crore in the corresponding quarter last year. Revenue from operations rose 20% year-on-year to Rs 1,800 crore from Rs 1,506 crore.

R&D investment stood at Rs 77.2 crore during the quarter, while adjusted EBITDA grew 37% year-on-year, with the margin at 28%. Its CDMO business contributed 50% of total revenue and grew 20% year-on-year, while the B2B business accounted for the remaining 50% and grew 19%.

Gland Pharma shares have gained 69.96% so far in 2026. The company had a market capitalisation of Rs 47,920.34 crore on the BSE as of September 3, 2026.

Established in Hyderabad in 1978, Gland Pharma has grown from a contract manufacturer of small-volume liquid parenteral products into a leading generic injectable manufacturer. The company has a presence across 60 countries, including the US, Europe, Canada, Australia and India.

Gland Pharma primarily operates under a business-to-business (B2B) model and specialises in the research and development, manufacturing and marketing of complex injectable products.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)